ClinVar Miner

Submissions for variant NM_000257.4(MYH7):c.4135G>A (p.Ala1379Thr)

gnomAD frequency: 0.00001  dbSNP: rs397516202
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000629005 SCV000059538 pathogenic Hypertrophic cardiomyopathy 2022-02-07 criteria provided, single submitter clinical testing The p.Ala1379Thr variant in MYH7 has been reported in >10 families with HCM and segregated with disease in >15 affected relatives (Blair 2002, Richard 2003, Zou 2013, Burns 2016, Walsh 2017, LMM data). It has also been identified in 1/35440 Latino chromosomes in gnomAD ( and has been reported in ClinVar (Variation ID 42993). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for HCM in an autosomal dominant manner. ACMG/AMP criteria applied: PS4, PP1_Strong, PM2_Supporting, PP3.
GeneDx RCV000505712 SCV000208572 pathogenic not provided 2023-01-23 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25961035, 28166811, 30466861, 23283745, 16918501, 11861410, 22199023, 21310275, 12707239, 27532257, 27247418, 28790153, 28615295, 33631351, 27387980, 33673806, 32894683, 33087929, 27535533, 11861413, 26582918, 35935646, 34076677)
Agnes Ginges Centre for Molecular Cardiology, Centenary Institute RCV000629005 SCV000212637 pathogenic Hypertrophic cardiomyopathy 2018-08-23 criteria provided, single submitter research MYH7 Ala1379Thr has previously been identified in multple HCM cases (Walsh R et al., 2017; Zou Y et al., 2013; Richard P et al., 2003; Blair E et al., 2002). Familial analysis by Blair E. et al. (2002) demonstrated strong segregation of this variant with disease phenotype. We have detected this variant in 4 unrelated HCM families, 3 of which were reported previously (Ingles J et al., 2017; Burns et al., 2017) and segregated to an additional 3 affected family members in one family. Furthermore, this variant is absent in both the Exome Aggregation Consortium dataset ( and 1000 genomes project ( In silico tools SIFT, MutationTaster and PolyPhen-2 predict that the variant is deleterious. More specifically, a tool designed to predict the effects of missense variants in HCM genes (Jordan DM, et al., 2011), predicts this MYH7 Ala1379Thr variant to be "Pathogenic". Based on the adapted ACMG guidelines (Kelly MA, et al., 2018), this variant has been identified in more than 10 unrelated probands (PS4_Strong), has strong segregation data (PP1_Strong), is rare in the general population (PM2) and in silico tools predict that it is deleterious (PP3), therefore we classify MYH7 Ala1379Thr as 'pathogenic'.
Center for Medical Genetics Ghent, University of Ghent RCV000162337 SCV000299237 likely pathogenic Hypertrophic cardiomyopathy 1 2016-02-18 criteria provided, single submitter clinical testing
Ambry Genetics RCV000619392 SCV000737001 pathogenic Cardiovascular phenotype 2023-01-25 criteria provided, single submitter clinical testing The p.A1379T pathogenic mutation (also known as c.4135G>A), located in coding exon 28 of the MYH7 gene, results from a G to A substitution at nucleotide position 4135. The alanine at codon 1379 is replaced by threonine, an amino acid with some similar properties. This variant was reported to segregate with hypertrophic cardiomyopathy (HCM) or related features in multiple individuals across three HCM proband-identified families, and has also been detected in additional HCM cohorts (Blair E et al. Circ Res. 2002;90:263-9; Zou Y et al. Mol Biol Rep. 2013;40:3969-76; Richard P et al. Circulation. 2003;107:2227-32; Walsh R et al. Genet. Med., 2017 Feb;19:192-203). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000629005 SCV000749915 pathogenic Hypertrophic cardiomyopathy 2024-01-30 criteria provided, single submitter clinical testing This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 1379 of the MYH7 protein (p.Ala1379Thr). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individuals with hypertrophic cardiomyopathy (PMID: 11861413, 12707239, 23283745, 27247418, 27532257, 28790153). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 42993). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYH7 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000035887 SCV001337987 pathogenic Primary familial hypertrophic cardiomyopathy 2020-01-27 criteria provided, single submitter clinical testing Variant summary: MYH7 c.4135G>A (p.Ala1379Thr) results in a non-conservative amino acid change located in the Myosin tail domain (IPR002928) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251464 control chromosomes (gnomAD). c.4135G>A has been reported in the literature in multiple individuals affected with Hypertrophic Cardiomyopathy (Richard_2003, Blair_2002, Ross_2017). Blair_2002 reported that this variant segregated with disease in three unrelated families and was not present in 200 control chromosomes. These data indicate that the variant is very likely to be associated with disease. At least one publication, Flashman_2007, reports this variant has no effect on interaction with C10 of cMyBP-C. Four ClinVar submitters (evaluation after 2014) cite the variant as pathogenic (3x) and likely pathogenic (1x). Based on the evidence outlined above, the variant was classified as pathogenic.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV003149622 SCV003838748 pathogenic Cardiomyopathy 2021-08-20 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000035887 SCV000188802 likely pathogenic Primary familial hypertrophic cardiomyopathy 2013-10-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.